Medications

Generic competition cuts Merck's Q1 sales, profit

Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Medical research

Is a better sleeping pill on the way?

(HealthDay)—A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.

Cardiology

ACC: Niacin/Laropiprant no benefit in vascular disease

(HealthDay)—For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious side effects, according ...

Other

Merck Q4 net profit more than doubles

Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

Other

Generic competition, charges cut Merck Q4 profit (Update)

Merck & Co.'s fourth-quarter profit fell 7 percent because of hits from generic competition and one-time charges, and the company pushed back plans to seek approval of a key experimental osteoporosis drug.

page 9 from 14